Comparative Pharmacology
Head-to-head clinical analysis: ATONCY versus SUNOSI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATONCY versus SUNOSI.
ATONCY vs SUNOSI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Atoncy (pemigatinib) is a selective fibroblast growth factor receptor (FGFR) inhibitor. It binds to and inhibits FGFR1, FGFR2, and FGFR3, thereby blocking downstream signaling pathways involved in cell proliferation and survival.
Selective dopamine and norepinephrine reuptake inhibitor; also acts as a TAAR1 agonist, increasing cAMP levels in monoamine neurons.
ATONCY (crizotinib) 250 mg orally twice daily.
75 mg orally once daily upon awakening.
None Documented
None Documented
Terminal elimination half-life is approximately 12 hours (range 10-14 hours) in patients with normal renal function; prolonged to 24-36 hours in moderate renal impairment (CrCl 30-50 mL/min) and up to 48 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is approximately 9.5 hours in healthy adults; clinically relevant for once-daily dosing.
Primarily renal excretion as unchanged drug (approximately 70%) and as metabolites (approximately 20%); biliary/fecal excretion accounts for the remaining 10%.
Primarily renal elimination (approximately 95% as unchanged drug and metabolites); biliary/fecal excretion accounts for <5%.
Category C
Category C
Norepinephrine Reuptake Inhibitor
Dopamine and Norepinephrine Reuptake Inhibitor